Summary
• InMed Pharmaceuticals Inc. share price increased 26.8% pre-market to $1.56 following successful pharmacokinetic studies for Alzheimer’s candidate INM-901.
• Positive study results highlighted favorable bioavailability for the oral formulation, advancing plans for upcoming clinical trials.
• The company filed an 8-K post-announcement to ensure regulatory compliance and keep investors informed about developments.
InMed Pharmaceuticals Inc. (INM) is enjoying a robust pre-market rally, with shares priced at $1.56, reflecting a significant increase of 26.8% from the last close of $1.23. This surge follows news concerning the successful completion of pharmacokinetic studies for its Alzheimer’s disease candidate, INM-901, which seems to have captured investor interest ahead of the trading session.
Positive Study Results Propel Shares Higher
On November 18, InMed Pharmaceuticals announced critical advancements regarding INM-901, its treatment aimed at Alzheimer’s disease. The data revealed a favorable bioavailability profile for the oral formulation, paving the way for the design and planning of its upcoming first-in-human clinical trials. The company emphasized preparations for a pre-Investigational New Drug (IND) meeting with the FDA, highlighting the study’s importance in advancing its drug candidate’s development.
These developments not only exhibit progress in InMed’s pipeline but also align with its strategic focus on addressing high unmet medical needs, sparking renewed interest from investors.
[chart type=’press-releases’ value=’INM’]
Trading Overview and Performance Metrics
With the recent price action, the stock’s technical indicators reflect noteworthy volatility. The current average volume over the last three months stands at 249,850, while the past ten-day average volume is considerably higher at 1,922,055. Additionally, the company’s recent performance metrics show some resistance as shares are still down 67% on a yearly basis, demonstrating the challenges InMed faces in the market.
The stock’s Relative Strength Index (RSI) stands at 24.21, indicating potential oversold conditions. The short-term movement contrasts with a persistent downtrend; however, today’s positive announcement appears to be a turning point, at least in the short term.
[chart type=’price’ value=’INM’]
Regulatory Filings
Following the announcement of the pharmacokinetic study results, InMed filed an 8-K on November 19, providing further details to stay in compliance with regulatory disclosure requirements. This filing is part of the company’s standard practice to keep investors informed about significant corporate events and milestones related to its ongoing developments.
[chart type=’sec’ value=’INM’]
Conclusion
The pre-market gains for InMed Pharmaceuticals reflect investor enthusiasm resulting from the recent positive drug development news. With the focus now on advancing INM-901 through clinical trials, the trading activity will be closely scrutinized. As the stock enters regular trading hours, participants will likely monitor volume and momentum trends to gauge how sentiment continues to evolve.